349 related articles for article (PubMed ID: 12006527)
21. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.
Russo A; Corsale S; Agnese V; Macaluso M; Cascio S; Bruno L; Surmacz E; Dardanoni G; Valerio MR; Vieni S; Restivo S; Fulfaro F; Tomasino RM; Gebbia N; Bazan V
J Cell Physiol; 2006 Jan; 206(1):181-8. PubMed ID: 15965904
[TBL] [Abstract][Full Text] [Related]
22. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas.
Parhar P; Ezer R; Shao Y; Allen JC; Miller DC; Newcomb EW
Brain Res Mol Brain Res; 2005 Jun; 137(1-2):98-103. PubMed ID: 15950766
[TBL] [Abstract][Full Text] [Related]
23. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
24. TP53 mutations in astrocytic gliomas: an association with histological grade, TP53 codon 72 polymorphism and p53 expression.
Faria MH; Neves Filho EH; Alves MK; Burbano RM; de Moraes Filho MO; Rabenhorst SH
APMIS; 2012 Nov; 120(11):882-9. PubMed ID: 23009112
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
[TBL] [Abstract][Full Text] [Related]
26. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
[TBL] [Abstract][Full Text] [Related]
27. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
28. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
[TBL] [Abstract][Full Text] [Related]
29. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
[TBL] [Abstract][Full Text] [Related]
30. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
31. p53 mutation and protein alteration in 50 gliomas. Retrospective study by DNA-sequencing techniques and immunohistochemistry.
von Eckardstein K; Gries H; Bolik E; Cervós-Navarro J; Tschairkin IN; Patt S
Histol Histopathol; 1997 Jul; 12(3):611-6. PubMed ID: 9225141
[TBL] [Abstract][Full Text] [Related]
32. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.
Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J
Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176
[TBL] [Abstract][Full Text] [Related]
33. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
Licitra L; Suardi S; Bossi P; Locati LD; Mariani L; Quattrone P; Lo Vullo S; Oggionni M; Olmi P; Cantù G; Pierotti MA; Pilotti S
J Clin Oncol; 2004 Dec; 22(24):4901-6. PubMed ID: 15611505
[TBL] [Abstract][Full Text] [Related]
34. p53 abnormality and tumor invasion in patients with malignant astrocytoma.
Momota H; Narita Y; Matsushita Y; Miyakita Y; Shibui S
Brain Tumor Pathol; 2010 Oct; 27(2):95-101. PubMed ID: 21046311
[TBL] [Abstract][Full Text] [Related]
35. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
36. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
37. Expression of p53 and prognosis in children with malignant gliomas.
Pollack IF; Finkelstein SD; Woods J; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Boyett JM; Finlay JL; Sposto R;
N Engl J Med; 2002 Feb; 346(6):420-7. PubMed ID: 11832530
[TBL] [Abstract][Full Text] [Related]
38. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
[TBL] [Abstract][Full Text] [Related]
39. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor.
Ishii N; Tada M; Hamou MF; Janzer RC; Meagher-Villemure K; Wiestler OD; Tribolet N; Van Meir EG
Oncogene; 1999 Oct; 18(43):5870-8. PubMed ID: 10557074
[TBL] [Abstract][Full Text] [Related]
40. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Krüger S; Lange I; Kausch I; Feller AC
Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]